Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.46 |
| ▸ | BRAF | P15056 | 6/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.43 |
| ▸ | GSK3A | P49840 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077186 | 0.92 | ABL1 (0.47) | ABL1BRAFGSK3BGSK3A | |
| SCHEMBL1079128 | 0.91 | ABL1 (0.47) | ABL1BRAFGSK3BGSK3AMAPT | |
| SCHEMBL1079743 | 0.89 | BRAF (0.42) | ABL1BRAF | |
| SCHEMBL1077835 | 0.89 | ABL1 (0.47) | ABL1BRAFGSK3BGSK3A | |
| SCHEMBL1077657 | 0.89 | MAPK14 (0.47) | ABL1BRAF | |
| SCHEMBL1078499 | 0.84 | ABL1 (0.52) | ABL1BRAF | |
| SCHEMBL1077797 | 0.82 | BTK (0.42) | ABL1BRAF | |
| SCHEMBL1078407 | 0.82 | LCK (0.48) | ABL1BRAF | |
| SCHEMBL1077238 | 0.81 | BTK (0.42) | ABL1BRAF | |
| SCHEMBL1149288 | 0.81 | LCK (0.48) | ABL1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269993-B1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269993-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | H1-2, H1-3, H1-0 | ABL1 47/4885BRAF 2498/4885GSK3B 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.